NRC - National Research Corporation
Unit 1 authorized to operate through 2054 and Unit 2 through 2058 ATLANTA, June 15, 2026 /PRNewswire/ -- Georgia Power announced today that the U.S. Nuclear Regulatory Commission (NRC) has approved the subsequent license renewal for the Edwin I. Hatch Nuclear Plant near Baxley.
Healthcare organizations face rising expectations and constrained resources as they work to improve patient experience, strengthen workforce engagement, sustai
LINCOLN, Neb.--(BUSINESS WIRE)-- #HealthcareExperience--Healthcare organizations face rising expectations and constrained resources as they work to improve patient experience, strengthen workforce engagement, sustain safe care, and translate insight into measurable performance. NRC Health, a recognized leader in healthcare experience management, today announced a strategic partnership with the Healthcare Experience Foundation (HXF) to expand the expertise and programs available to help healthcare leaders meet these de.
Hadron Energy, Inc. (Nasdaq: HDRN) ("Hadron Energy" or the "Company"), an advanced nuclear technology company, today announced that the staff of the U.S. Nucle
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Hadron Energy, Inc. (Nasdaq: HDRN) ("Hadron Energy" or the "Company"), an advanced nuclear technology company, today announced that the staff of the U.S. Nuclear Regulatory Commission (NRC) has issued a final safety evaluation finding Revision 3 of the Company's Topical Report (TR), "Hadron Energy, Inc. Quality Assurance Program Description" (QAPD), acceptable for referencing in its future licensing applications under 10 CFR Part 52. The NRC staff's final.
[url="]The Governance Institute (TGI)[/url], a service of [url="]NRC Health[/url], today announced the formation of a [url="]Blue Ribbon Committee on Health Sy
LINCOLN, Neb.,--(BUSINESS WIRE)-- #HealthcareBoards--The Governance Institute (TGI), a service of NRC Health, today announced the formation of a Blue Ribbon Committee on Health System Governance. The Committee will convene this summer to help inform the next phase of healthcare governance practice and work to revitalize TGI's approach to board assessment in response to the scale, complexity, and system interdependence facing modern not-for-profit health systems. The formation of the Committee follows the release o.
SMR's dual NRC Part 52 approvals give it a licensing head start that could speed deployments for AI sites and industry.
The nuclear sector is delivering concrete progress on multiple advanced reactor programs. Recent weeks brought a positive environmental determination for an X-energy (XE) project, Nuclear Regulatory Commission (NRC) approvals for key technical documents from Oklo (OKLO) and Terrestrial Energy (IMSR), and the start of prototype manufacturing for critical reactor components.
Represents a key milestone on the project's NRC Construction Permit Application Project supported by U.S. DOE's Advanced Reactor Demonstration Program MIDLAND, Mich. and ROCKVILLE, Md.
Edmonton, Alberta – May 13, 2026 - TheNewswire – Innovotech Inc. (TSX Venture Exchange: IOT ; OTCQB: IOTCF ) (“Innovotech” or the “Company”) reports that its subsidiary Innovotech Labs Corporation is receiving advisory services and research and development funding of up to $234,000 CAD from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support the development of new antimicrobial testing services for use with medical devices such as catheters, implants, and wound dressings. The new testing methods align with changes in international regulatory standards and medical device manufacturers' needs in the areas of proliferation, biofilm formation, and translocation of microorganisms. This work builds on foundational development started last year and advances it into more robust, fit-for-purpose testing. As customer programs expand, manufacturers are requesting more advanced testing that better reflects real-world use and provides clearer decision-making data. Strengthening these capabilities will expand the Company service offerings, support regulatory readiness, and help customers demonstrate device safety and performance more effectively.
Vancouver, British Columbia--(Newsfile Corp. - May 13, 2026) - Nations Royalty Corp. (TSXV: NRC) (OTCQX: NRYCF) (FSE: Y96) ("Nations Royalty" or the "Company") is pleased to announce that it has granted, effective May 12, 2026, incentive stock options to certain directors, officers, employees, and consultants of the Company to acquire an aggregate of 934,000 common shares in the capital of the Company at an exercise price of $0.955 (the "Options"), being the closing price of the Company's common shares on the TSX Venture Exchange on May 12, 2026. The Options are exercisable for a period of five (5) years from the date of grant and will vest as follows: one-third (1/3) on the date of grant, one-third (1/3) after 12 months, and the remaining one-third (1/3) after 24 months from the date of grant.
NRC Health (NRC) Q1 2026 Earnings Call Transcript
LINCOLN, Neb.--(BUSINESS WIRE)--NRC Health (NASDAQ: NRC), a leader in healthcare experience improvement solutions, today announced results for the first quarter 2026. "We delivered a strong start to 2026, with record Total Recurring Contract Value and our first quarter of year-over-year revenue growth since 2023, reflecting the tangible momentum building across our business,” said Trent Green, CEO of NRC Health. “The signing of the largest deal in our 45-year history is a powerful validation of.
JENSEN BEACH, Fla., April 28, 2026 /PRNewswire/ -- Following a rigorous multi-year application and review process, the U.S. Nuclear Regulatory Commission (NRC) has approved subsequent license renewals for St. Lucie Nuclear Plant Units 1 and 2, extending operations through 2056 and 2063, respectively.
New York, N.Y., April 28, 2026 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear micro modular reactor (MMR) and technology company focused on developing clean energy solutions, today issued a statement regarding recent regulatory developments from the U.S. Nuclear Regulatory Commission (“NRC”), including the finalization of a new rule, known as Part 53, and the issuance of a proposed new rule known as Part 57. These rules are being advanced pursuant to Congressional direction under the Nuclear Energy Innovation and Modernization Act of 2019, known as NEIMA.
New York, New York--(Newsfile Corp. - April 28, 2026) - NANO Nuclear Energy Inc. (NASDAQ: NNE) ("NANO Nuclear" or "the Company"), a leading advanced nuclear micro modular reactor (MMR) and technology company focused on developing clean energy solutions, today issued a statement regarding recent regulatory developments from the U.S. Nuclear Regulatory Commission ("NRC"), including the finalization of a new rule, known as Part 53, and the issuance of a proposed new rule known as Part 57. These rules are being advanced pursuant to Congressional direction under the Nuclear Energy Innovation and Modernization Act of 2019, known as NEIMA.
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--The Governance Institute (TGI), a service of NRC Health, today released Falling Behind: Health System Operations Are Advancing Faster than Governance, a new governance brief examining whether today's health system governance models are keeping pace with the scale, complexity, and speed of modern healthcare. The report was released during TGI's 250th Leadership Conference in Scottsdale, Arizona, where healthcare trustees, executives, physician leaders, and gov.
CALGARY, Alberta, April 24, 2026 (GLOBE NEWSWIRE) -- Questor Technology Inc. ("Questor" or the "Company") (TSX-V: QST) today announced that the National Research Council of Canada ("NRC") has awarded the Company $1.9 million to complete development and launch commercialization of Questor's 1500kW Rankine Cycle ("ORC") Heat-to-Power Generation System.
CALGARY, Alberta, April 16, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), a biotechnology company developing novel therapies for neurological and neurodevelopmental disorders, today announces it has identified two lead pediatric-friendly liquid formulations of its patented lead compound, MB-204. This work was supported by a National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) grant and focused on the design of a small-volume oral liquid formulation of MB-204.